A 38-year-old woman from rural Maharashtra presents with progressive fatigue, dyspnea on exertion, and jaundice for 3 weeks. On examination, she has pallor, icterus, and mild splenomegaly. Laboratory findings: Hb 7.2 g/dL, reticulocyte count 8%, total bilirubin 4.8 mg/dL (indirect 4.2 mg/dL), LDH 890 U/L, haptoglobin <10 mg/dL. Peripheral blood smear shows spherocytes, polychromasia, and occasional nucleated RBCs. What is the most appropriate next step in management?

Explanation

## Clinical Scenario Analysis This patient presents with clinical and laboratory features consistent with **hemolytic anemia**: jaundice, elevated indirect bilirubin, elevated LDH, low haptoglobin, reticulocytosis, and spherocytes on smear. ## Diagnostic Approach to Hemolytic Anemia **Key Point:** The peripheral blood smear findings (spherocytes, polychromasia, nucleated RBCs) suggest an intrinsic RBC defect or immune-mediated hemolysis. The next critical step is to **differentiate the etiology** before treatment. ### Why DAT and Osmotic Fragility Test? | Test | Purpose | Expected Finding in This Case | |------|---------|-------------------------------| | **Direct Antiglobulin Test (DAT/Coombs)** | Detects IgG/C3 on RBC surface | Positive if autoimmune hemolytic anemia (AIHA) | | **Osmotic Fragility Test** | Assesses RBC membrane integrity | Increased fragility if hereditary spherocytosis (HS) | **High-Yield:** Both tests are **essential before initiating treatment** because: - **AIHA** (DAT-positive) → corticosteroids are first-line - **HS** (osmotic fragility positive, DAT-negative) → splenectomy is definitive; steroids are ineffective - Misdiagnosis leads to inappropriate therapy and poor outcomes ## Why This Is the Next Step 1. The smear findings alone cannot distinguish AIHA from HS 2. Both present with spherocytes and hemolysis 3. Treatment differs fundamentally between the two 4. DAT and osmotic fragility are **rapid, non-invasive, and diagnostic** **Clinical Pearl:** In Indian populations, hereditary spherocytosis is less common than AIHA, but the clinical presentation is identical — testing is mandatory before committing to steroids. [cite:Robbins 10e Ch 14]